Prescribed medicine use and extent of off-label use according to age in a nationwide sample of Australian children
- PMID: 35172017
- PMCID: PMC9540111
- DOI: 10.1111/ppe.12870
Prescribed medicine use and extent of off-label use according to age in a nationwide sample of Australian children
Abstract
Background: Medicine prescribing for children is impacted by a lack of paediatric-specific dosing, efficacy and safety data for many medicines.
Objectives: To estimate the prevalence of medicine use among children and the rate of 'off-label' prescribing according to age at dispensing.
Methods: We used population-wide primarily outpatient dispensing claims data for 15% of Australian children (0-17 years), 2013-2017 (n = 840,190). We estimated prescribed medicine use and 'off-label' medicine use according to the child's age (<1 year, 1-5 years, 6-11 years, 12-17 years) defined as medicines without age-appropriate dose recommendations in regulator-approved product information. Within off-label medicines, we also identified medicines with and without age-specific dose recommendations in a national prescribing guide, the Australian Medicines Handbook Children's Dosing Companion (AMH CDC).
Results: The overall dispensing rate was 2.0 dispensings per child per year. The medicines with the highest average yearly prevalence were systemic antibiotics (435.3 per 1000 children), greatest in children 1-5 years (546.9 per 1000). Other common medicine classes were systemic corticosteroids (92.7 per 1000), respiratory medicines (91.2 per 1000), acid-suppressing medicines in children <1 year (47.2 per 1000), antidepressants in children 12-17 years (40.3 per 1000) and psychostimulants in children 6-11 years (27.0 per 1000). We identified 12.2% of dispensings as off-label based on age, but 66.3% of these had age-specific dosing recommendations in the AMH CDC. Among children <1 year, off-label dispensings were commonly acid-suppressing medicines (35.5%) and topical hydrocortisone (33.1%); in children 6-11 years, off-label prescribing of clonidine (16.0%) and risperidone (13.1%) was common. Off-label dispensings were more likely to be prescribed by a specialist (21.7%) than on-label dispensings (7.5%).
Conclusions: Prescribed medicine use is common in children, with off-label dispensings for medicines without paediatric-specific dosing guidelines concentrated in classes such as acid-suppressing medicines and psychotropics. Our findings highlight a need for better evidence to support best-practice prescribing.
Keywords: Australia; attention deficit disorder with hyperactivity; gastroesophageal reflux; paediatrics; pharmacoepidemiology.
© 2022 The Authors. Paediatric and Perinatal Epidemiology published by John Wiley & Sons Ltd.
Conflict of interest statement
AS, CB, ML, HZ and SAP are employees of the Centre for Big Data Research in Health, UNSW Sydney which received funding in 2020 from AbbVie Australia to conduct research, unrelated to the submitted work. AbbVie did not have any knowledge of, or involvement in, the present study. SAP is a member of the Drug Utilisation Sub Committee of the Pharmaceutical Benefits Advisory Committee. The views expressed in this paper do not represent those of the Committee.
Figures
Comment in
-
Pharmacoepidemiology: A key complementary tool to evaluate the paediatric exposome.Paediatr Perinat Epidemiol. 2022 Sep;36(5):738-740. doi: 10.1111/ppe.12907. Epub 2022 Jul 12. Paediatr Perinat Epidemiol. 2022. PMID: 35821649 No abstract available.
Similar articles
-
Off-label and unlicensed utilisation of medicines in a French paediatric hospital.Int J Clin Pharm. 2015 Dec;37(6):1222-7. doi: 10.1007/s11096-015-0191-3. Epub 2015 Sep 22. Int J Clin Pharm. 2015. PMID: 26394784
-
Changes in anticonvulsant prescribing for Australian children: implications for Quality Use of Medicines.J Paediatr Child Health. 2012 Jun;48(6):490-5. doi: 10.1111/j.1440-1754.2011.02223.x. Epub 2011 Nov 3. J Paediatr Child Health. 2012. PMID: 22050665
-
Rates of psychotropic medicine prescribing in paediatric populations in Australian general practice from 2000-2016.Eur Neuropsychopharmacol. 2022 Dec;65:68-78. doi: 10.1016/j.euroneuro.2022.09.007. Epub 2022 Nov 23. Eur Neuropsychopharmacol. 2022. PMID: 36434887
-
Pediatric Off-Label and Unlicensed Drug Use and Its Implications.Curr Clin Pharmacol. 2017;12(1):18-25. doi: 10.2174/1574884712666170317161935. Curr Clin Pharmacol. 2017. PMID: 28322168 Review.
-
The extent to which off-patent registered prescription medicines are used for off-label indications in Australia: A scoping review.PLoS One. 2021 Dec 3;16(12):e0261022. doi: 10.1371/journal.pone.0261022. eCollection 2021. PLoS One. 2021. PMID: 34860857 Free PMC article.
Cited by
-
Attention-deficit/hyperactivity disorder in Mozambique: an epidemiological investigation in a primary school sample.Braz J Psychiatry. 2024;46:e20233343. doi: 10.47626/1516-4446-2023-3343. Epub 2024 Jan 19. Braz J Psychiatry. 2024. PMID: 38243805 Free PMC article.
-
Off-Label Prescribing in Pediatric Population-Literature Review for 2012-2022.Pharmaceutics. 2023 Nov 21;15(12):2652. doi: 10.3390/pharmaceutics15122652. Pharmaceutics. 2023. PMID: 38139994 Free PMC article. Review.
-
Ongoing challenges of off-label prescribing.Aust Prescr. 2023 Dec;46(4):86-89. doi: 10.18773/austprescr.2023.022. Aust Prescr. 2023. PMID: 38152320 Free PMC article. Review.
-
Paediatric off-label use of drugs in Gansu, China: a multicentre cross-sectional study.BMJ Open. 2024 May 13;14(5):e078126. doi: 10.1136/bmjopen-2023-078126. BMJ Open. 2024. PMID: 38740506 Free PMC article.
-
Suitability of paediatric legislation beyond the USA and Europe: a qualitative study on access to paediatric medicines.BMJ Public Health. 2024 Feb 7;2(1):e000264. doi: 10.1136/bmjph-2023-000264. eCollection 2024 Jun. BMJ Public Health. 2024. PMID: 40018188 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical